ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Novyra Pharmachem Ltd reported revenue from operations of ₹4.2 Cr and net profit of ₹0 Cr for Q2 FY27.
Novyra Pharmachem will hold a board meeting on 2 November 2026 to consider unaudited Q2 results. Agenda items remain proposed until the meeting.
Novyra Pharmachem Ltd filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.
Novyra Pharmachem intimated BSE of a change in its official email ID under Reg 30. The update is purely administrative with no business or financial impact.
The company has officially changed its name from Bansisons Tea Industries Limited to Novyra Pharmachem Limited. This change reflects the company's expansion into the pharmaceutical sector.
Bansisons Tea Industries Ltd reported revenue from operations of ₹1.7 Cr and net profit of ₹0 Cr for Q1 FY27.
Novyra Pharmachem Limited has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Novyra Pharmachem Limited has updated its official website address. The change is being intimated to the exchange for record-keeping purposes.
Bansisons Tea Industries Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Novyra Pharmachem Limited held its 39th AGM on June 25, 2026 via video conference. The meeting adopted audited accounts, re-appointed a director and approved a capital reduction scheme.
Novyra Pharmachem Limited released its 39th Annual Report for FY2025-26. The report includes notice for the AGM and a proposed scheme for capital reduction.
Novyra Pharmachem Limited reported zero deviation in the utilization of ₹0.13 Crore raised via preferential issue. Funds were fully utilized for working capital requirements as intended.
Novyra Pharmachem Limited scheduled its 39th AGM for June 25, 2026, via VC/OAVM. Revised e-voting and book closure dates are also confirmed for shareholders.
Novyra Pharmachem approved a capital reduction proposal and scheduled its 39th AGM for June 19, 2026. These administrative steps align corporate structure with long-term strategy.